NCT05053334 - Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair | Biotech Hunter

Enrollment

165

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

January 10, 2024

Study Completion Date

January 10, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

Omalizumab Prefilled Syringe

150mg/ml of Omalizumab prefilled syringe

Trial Locations (3)

Auckland Clinical Studies Ltd (NZCR OpCo Limited), Grafton

Q-Pharm Pty Ltd, Herston

Christchurch Clinical Studies Trust Ltd (NZCR OpCo Limited), Christchurch